Biomaterials can fundamentally alter the performance of everyday products. The difficulty is finding methods that allow you to make these biomaterials at sufficient scale. Zentraxa is solving this problem using its proprietary Zentide platform which can produce novel peptides with unique properties.
Founded in 2017 as a spin-out from the University of Bristol, Zentraxa specialises in the design, production & testing of biomaterials for medical and industrial purposes. The company aims to become one of the front-runners in developing novel biomaterials leveraging its unique process and sustainable, bespoke solutions.
"Following investment from Elbow Beach Capital, Zentraxa is excited to further develop our unique platform technology and to design new, innovative biomaterial solutions with our commercial partners. This funding from Elbow Beach Capital and our other investors will allow us to achieve significant R&D and commercial milestones in the coming months. I look forward to working closely with JP and the Elbow Beach team as we work towards achieving these milestones.” - Jonathan Wogel, Executive Chair & Director